ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success
ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $8, H.C.
Immunitybio Inc. (IBRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Anson Investments Amin Nathoo And Moez Kassam | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | 0 | $0 | 0% | ||
| 4. | 0 | $0 | 0% | ||
| 5. | Sculptor Capital Daniel S. Och | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 485 | $1,333.75 | 71,915 | 2023-06-05 | Filing | |
| $2.77 | 48,000 | $132,960.00 | 71,430 | 2023-06-05 | Filing | |
| $2.72 | 23,430 | $63,729.60 | 23,430 | 2023-06-05 | Filing | |
| $2.90 | 10,000 | $29,000.00 | 25,000 | 2023-06-02 | Filing | |
| $2.80 | 10,000 | $28,000.00 | 15,000 | 2023-06-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.12 | 14,801 | $149,795.00 | 200,617 | 2021-08-23 | Filing | |
| $10.00 | 9,976 | $99,807.88 | 215,418 | 2021-08-20 | Filing | |
| $10.03 | 2,133 | $21,389.08 | 225,394 | 2021-08-18 | Filing | |
| $10.12 | 43,398 | $439,361.35 | 227,527 | 2021-08-17 | Filing | |
| $16.18 | 88,787 | $1,436,822.26 | 3,102,507 | 2021-05-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
ImmunityBio (IBRX) Attains FDA's Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc.
13 Best Long-Term Penny Stocks to Buy According to Analysts
On June 18, Société Générale's Subadra Rajappa appeared on CNBC to talk about her expectations from the Fed.
ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion
We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at where ImmunityBio, Inc.
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ImmunityBio, Inc.
Why ImmunityBio, Inc. (IBRX) Surged On Thursday
We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild.
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT
In a research note, the analyst told investors that the rating is based on the development of the company's ANKTIVA, t-haNK & M-ceNK cell therapies, and DNA vaccines, which combat cancer by supporting...
Why ImmunityBio, Inc. (IBRX) Crashed Today
We recently published a list of 10 Firms Drenched in Red Today. In this article, we are going to take a look at where ImmunityBio, Inc.
Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever”
We recently published a list of Jim Cramer’s Recent Thoughts on These 15 Stocks.
Billionaire Hedge Funds
